Experience with the drug Covirvin (AВ21 D+) in COVID-19 convalescents
The novel coronavirus infection caused by the SARS-CoV-2 virus remains a significant public health problem. Further study of the pathogenetic mechanisms of the disease, its complications, as well as the development and improvement of approaches to personalized therapy and patient rehabilitation remain relevant. Therefore, the search for approaches to correcting intestinal microbiome disturbances as part of the comprehensive treatment of COVID-19 is particularly important. The use of probiotics is considered a promising approach in this context.Ponezheva Zh.B., Martynova N.S., Mannanova I.V., Lazareva E.N.
Objective. Evaluation of the clinical efficacy of the combined probiotic Covirvin (AB21 D+) in COVID-19 convalescents.
Materials and methods. The study involved 100 patients—59 men and 41 women. 42 of them received a probiotic supplement, 1 capsule daily for 30 days, after completing inpatient treatment. Clinical, laboratory, immunological, microbiological, instrumental, and statistical methods were used.
Results. The probiotic complex Covirvin (AB21 D+) demonstrated significant clinical efficacy: it reduced the severity and alleviated clinical manifestations of the disease, reduced the severity of systemic inflammatory changes, and restored the balance of the intestinal microbiome (increased normal symbiotic flora and reduced the number of opportunistic bacteria).
Conclusion. The study results demonstrate the effectiveness of the probiotic mixture Covirvin (AB21 D+) containing Lactiplantibacillus plantarum, Pediococcus acidilactici, and vitamin D3. Its use helps reduce systemic inflammation, normalize the microbiome, and significantly improve patients’ quality of life. This opens up prospects for the development of pathogenetically based, microbiome-focused approaches to COVID-19 therapy, including the prevention of post-COVID complications and restoration of immune homeostasis.
Keywords
COVID-19
microbiome
MIP-1α
MIP-1β
sCD14
immune response
dysbiosis
References
- Стома И.О. Микробиом в медицине: руководство для врачей. М.: ГЭОТАР-Медиа, 2024. 320 с. [Stoma I.O. Microbiome in Medicine: A Guide for Physicians. Moscow: GEOTAR-Media, 2024. 320 p. (In Russ.)].
- Горелов А.В., Усенко Д.В. Микробиом при новой коронавирусной инфекции (COVID-19). Педиатрия им. Г.Н. Сперанского 2022; 101(3): 149–156. [Gorelov A.V., Usenko D.V. Microbiome and the new coronavirus infection (COVID-19). Pediatria n.a. G.N. Speransky 2022; 101(3): 149–156. (In Russ.)]. DOI: 10.24110/0031-403X-2022-101-3-149-156
- Битюмина Л.А., Куликова Н.Г., Плоскирева А.А., Горелов А.В. Влияние пандемии COVID-19 на структуру микробиоценоза кишечника. Эпидемиол. инфекц. болезни. Актуал. вопр. 2023; 13(2): 70–75. [Bityumina L.A., Kulikova N.G., Ploskireva A.A., Gorelov A.V. The impact of the COVID-19 pandemic on the structure of intestinal microbiocenosis. Epidemiоlоgy and infectious diseases. Сurrent items 2023; 13(2): 70–75. (In Russ.)]. DOI: 10.18565/epidem.2023.13.2.70-5
- Гришаева А.А., Понежева Ж.Б., Чанышев М.Д., Алешина Н.И., Мясникова М.А., Краснова С.В. Макрофагальные белки воспаления как маркеры тяжелого течения COVID-19. Эпидемиол. инфекц. болезни. Актуал. вопр. 2022; 12(1): 35–38. [Grishaeva A.A., Ponezheva Zh.B., Chanyshev M.D., Aleshina N.I., Myasnikova M.A., Krasnova S.V. Macrophage inflammatory proteins as markers of severe COVID-19 Epidemiology and Infectious Diseases. Сurrent items 2022; 12(1): 35–38. (In Russ.)]. DOI: 10.18565/epidem.2022.12.1.35-8
- Tufa А., Gebremariam T.H., Manyazewal T., Getinet T., Webb D.-L., Hellström P.M. et al. Inflammatory mediators profile in patients hospitalized with COVID- 19: a comparative study. Front. Immunol. 2022; 13: 964179. DOI: 10.3389/fimmu.2022.964179
- Chen M., Zhou H., Shen J., Wei M., Chen Zh., Chen X. et al. Oxymatrine alleviates NSAID-associated small bowel mucosal injury by regulating MIP-1/CCR1 signalling and gut microbiota. J. Pharmacol. Sci. 2024; 156(3): 149–160. DOI: 10.1016/j.jphs.2024.08.003
- Zingaropoli M.A., Nijhawan P., Carraro А., Pasculli P., Zuccalà P., Perri V. Increased sCD163 and sCD14 plasmatic levels and depletion of peripheral blood pro-inflammatory monocytes, myeloid and plasmacytoid dendritic cells in patients with severe COVID-19 pneumonia. Front. Immunol. 2021; 12: 627548. DOI: 10.3389/fimmu.2021.627548
- Verstockt B., Salas A., Sands B.E., Abraham C., Leibovitzh H., Neurath M. et al. IL-12 and IL-23 pathway inhibition in inflammatory bowel disease Nat. Rev. Gastroenterol. Hepatol. 2023; 20(7): 433–446. DOI: 10.1038/s41575-023-00768-1
- Simadibrata D.M., Lesmana E.. Gunawan J., Quigley E.M., Simadibrata M. A systematic review of gut microbiota profile in COVID-19 patients and among those who have recovered from COVID-19. J. Dig. Dis. 2023; 24(4): 244–261. DOI: 10.1111/1751-2980.13195.
- Farsi Y., Tahvildari A., Arbabi M., Vazife F., Sechi L.A., Shahidi Bonjar A.H. et al. Diagnostic, prognostic, and therapeutic roles of gut microbiota in COVID- 19: a comprehensive systematic review. Front. Cell Infect. Microbiol. 2022; 12: 804644. DOI: 10.3389/fcimb.2022.804644
- Ferreira-Junior A.S., Borgonovi T.F., De Salis L.V.V., Leite A.Z., Dantas A.S., Vilela De Salis G.V. et al. Detection of intestinal dysbiosis in post-COVID-19 patients one to eight months after acute disease resolution. J. Environ. Res. Public Health 2022; 19(16): 10189. DOI: 10.3390/ijerph191610189
- Tian Y., Sun K.Y., Meng T.Q., Ye Z., Guo S.M., Li Z.M. et al. Gut microbiota may not be fully restored in recovered COVID-19 patients after 3-month recovery. Front. Nutr. 2021; 8: 638825. DOI: 10.3389/fnut.2021.638825
- Ralli T., Saifi Z., Rathee A., Aeri V., Kohli K. Decoding the bidirectional relationship between gut microbiota and COVID-19. Heliyon 2023; 9(3): e13801. DOI: 10.1016/j.heliyon.2023.e13801
- Nandi S., Ahmed S., Saxena A. Exploring the Pathoprofiles of SARS-COV-2 Infected Human Gut–Lungs Microbiome Crosstalks. In: Kothari V., Kumar P., Ray S. (eds.). Probiotics, Prebiotics, Synbiotics, and Postbiotics. Singapore: Springer, 2023: 217–235. DOI: 10.1007/978-981-99-1463-0_12
- Albrich W.C., Ghosh T.S., Ahearn-Ford S., Mikaeloff F., Lunjani N., Forde B. et al. A high-risk gut microbiota configuration associates with fatal hyperinflammatory immune and metabolic responses to SARS-CoV-2. Gut Microbes 2022; 14(1): 2073131. DOI: 10.1080/19490976.2022.2073131
- Zhang D., Lu J., Dong B., Fang M.-Y., Xiong X., Qin X.-J. et al. Gut microbiota and its metabolic products in acute respiratory distress syndrome. Front. Immunol. 2024; 15: 1330021. DOI: 10.3389/fimmu.2024.1330021
- Li Z., Zhu G., Lei X., Tang L., Kong G., Shen M. et al. Genetic support of the causal association between gut microbiome and COVID-19: a bidirectional Mendelian randomization study. Front. Immunol. 2023; 14: 1217615. DOI: 10.3389/fimmu.2023.1217615
- Gutiérrez-Castrellón P., Gandara-Martí T., Abreu Y., Nieto-Rufino C.D., López-Orduña E., Jiménez-Escobar I. Probiotic improves symptomatic and viral clearance in COVID-19 outpatients: a randomized, quadruple-blinded, placebo-controlled trial. Gut Microbes 2022; 14(1): 2018899. DOI: 10.1080/19490976.2021.2018899
- Горелов А.В., ред. Клиническое руководство по инфекционным болезням. 2-ое изд. М.: Медконгресс. 2022. 472 c. [Gorelov A.V., ed. Clinical Guide on Infectious Diseases. 2nd ed. Moscow: Medkongress. 2022. 472 p. (In Russ.)].
- Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19): временные методические рекомендации, Версия 17 14.12.2022). М: Министерство здравоохранения РФ, 2022. 243 с. [Prevention, Diagnosis, and Treatment of Novel Coronavirus Infection (COVID-19): Interim Guidelines, Version 17, 14.12.2022). Moscow: Ministry of Health of the Russian Federation, 2022. 243 p. (In Russ.)].
- Мартынова Н.С., Понежева Ж.Б., Куликова Н.Г., Битюмина Л.А., Лазарева Е.Н., Усенко Д.В., Вдовина Е.Т. Системное воспаление и кишечный микробиоценоз при COVID-19: роль макрофагальных белков воспаления в патогенезе заболевания. РМЖ. Медицинское обозрение 2025; 9(5): 259–265. [Martynova N.S., Ponezheva Zh.B., Kulikova N.G., Bityumina L.A., Lazareva E.N., Usenko D.V., Vdovina E.T. Systemic inflammation and intestinal microbiocenosis in patients with COVID-19: a role of macrophage inflammatory proteins in the disease pathogenesis. Russian Medical Inquiry 2025; 9(5): 259–265 (In Russ.)]. DOI: 10.32364/2587-6821-2025-9-5-1
- Мартынова Н.С., Понежева Ж.Б., Лазарева Е.Н., Усенко Д.В., Николаева С.В., Швачкина Н.С. и др. Состояние микробиоценоза толстого кишечника у госпитализированных больных COVID- 19. Инфекционные болезни 2025; 23(2): 37–44. [Martynova N.S., Ponezheva Zh.B., Lazareva E.N., Usenko D.V., Nikolaeva S.V., Shvachkina N.S.et al. The state of colonic microbiocenosis in hospitalized COVID- 19 patients. Infectious Diseases 2025; 23(2): 37–44. (In Russ.)]. DOI: 10.20953/1729-9225-2025-2-37-44
About the Authors
Zhanna B. Ponezheva, MD, Leading Researcher, Clinical Department of Infectious Pathology, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; doktorim@mail.ru; https://orcid.org/0000-0002-6539-4878Nina S. Martynova, Postgraduate Student, Laboratory Researcher, Clinical Department of Infectious Pathology, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; :ninabistrova1210@mail.ru; https://orcid.org/0000-0002-7995-9702
Irina V. Mannanova, Cand. Med. Sci., Senior Researcher, Clinical Department of Infectious Pathology. Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; irinasemenova07@rambler.ru; https://orcid.org/0000-0003-2244-8810
Elena N. Lazareva, MD, Leading Researcher, Clinical Department of Infectious Pathology, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; elniklazareva@yandex.ru; https://orcid.org/0000-0002-6081-1740
Similar Articles
